Amicus Therapeutics
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
John Crowley speaks on drug development and the FDA
May 24, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amicus Therapeutics, John Crowley, biotech, drugs, pharma, pharmaceutical
Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.
Plot twist as FDA U-turns on Amicus drug decision
July 11, 2017Research and Development, Sales and Marketing Amicus Therapeutics, FDA, Galafold
The news continues to flow out of the FDA, as it grabs another headline by backtracking on its previous decision …
Amicus Therapeutics’ Fabry disease drug gets European regulatory support
April 4, 2016Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease
Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …
GSK-Amicus start late-stage trials of Fabry disease treatment
September 14, 2011Research and Development Amicus Therapeutics, Fabry disease, GSK
GlaxoSmithKline and Amicus Therapeutics are moving forward with their phase III programme for Fabry disease treatment Amigal. The first patient …
GSK signs rare diseases deal with Amicus
November 1, 2010Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones
GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
